AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...
Vietnam Investment Review on MSN3d
Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U S FDA Clearance of IND Application for ASC47 in Combination with SemaglutideASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single ...
Clinical Trials Arena on MSN2d
Ascletis’ muscle-preserving weight loss therapy sustains 40-day half-lifeThe company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback